Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function

American Heart Journal

Volumn 134, Issue 2 I, 1997, Pages 188-195

  Philbin, E F ^a   Rocco T A , Jr ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SYSTOLE; TREATMENT OUTCOME;

EID: 0030885766     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(97)70123-6     Document Type: Article

References (32)

1. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study N Engl J Med 316 1987 1429 1435
2. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
3. JN Cohn G Johnson S Zieshe F Cobb G Francis F Tritsani A comparison of enalapril with hydralazine-isosorbide in the treatment of chronic congestive heart failure N Engl J Med 325 1991 303 310
4. MA Pfeffer E Braunwald LA Moye L Basta EJ Brown TE Cuddy Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 327 1992 669 677
5. WJ Rogers DE Johnstone S Yusuf DH Weiner P Gallagher VA Bittner Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction J Am Coll Cardiol 23 1994 393 400
6. SI. Rajfer Perspective of the pharmaceutical industry on the development of new drugs for heart failure J Am Coll Cardiol 22 Suppl A 1993 198A 200A
7. SD Paul KM Kuntz KA Eagle NC. Weinstein Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure Arch Intern Med 154 1994 1143 1149
8. MA Konstam K Dracup MB Bottoroff NH Brooks RA Dacey SB Dunbar Quick reference guide for clinicians no. 11: heart failure: management of patients with left ventricular systolic dysfunction AHCPR Publication No. 94-0613 1994 United States Department of Health and Human Services Rockville (MD)
9. DE Johnstone A Abdulla JMO Arnold V Bernstein M Bourassa J Brophy Diagnosis and management of heart failure Can J Cardiol 10 1994 613 631
10. JB O’Connell MR Bristow Economic impact of heart failure in the United States: time for a different approach J Heart Lung Transplant 13 1994 S107 S112
11. EF Philbin C Andreou TA Rocco LJ Lynch SL. Baker Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals Am J Cardiol 77 1996 832 838
12. EF. Philbin Current community practices in heart failure: understanding the under utilization of angiotensin-converting enzyme inhibitors [abstract] J Am Coll Cardiol 29 Suppl A 1997 325A
13. JK Ghali S Kumar IC Sarkar R Horswell G Livaudais JP Murgo Factors influencing underutilization of angiotensin converting enzyme inhibitors in inpatients with heart failure [abstract] J Am Coll Cardiol 29 Suppl A 1997 324A
14. MM McDermott J Feinglass J Sy M. Gheorghiade Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy Am J Med 99 1995 629 635
15. RS Vasan EJ Benjamin D. Levy Prevalence, clinical features and prognosis of diastolic heart failure J Am Coll Cardiol 26 1995 1565 1574
16. EF Philbin LJ Lynch TA Rocco NW Lindenmuth K Ulrich M McCall Does quality improvement work? The Management to Improve Survival in Congestive Heart Failure (MISCHF) study Jt Comm J Qual Improv 22 1996 721 733
17. 3M Health Information Services, U.S. Health Care Financing Administration Diagnosis related groups definitions manual 1993 3M Health Information Services Wallingford (CT)
18. JN Cohn GR Johnson R Shabetai H Loeb F Tristani T Rector Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure Circulation 87 Suppl VI 1993 VI-5 VI-16
19. JA. Franciosa Why patients with heart failure die: hemodynamic and functional determinants of survival Circulation 75 Suppl IV 1987 IV-20 IV-27
20. AH Gradman PC. Deedwania Predictors of mortality in patients with heart failure Card Clinics 12 1994 25 35
21. CJ Girman C Kolman CL Liss JA Bolognese BS Binkowitz E. Stoner Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hypertrophy Prostate 29 1996 83 90
22. HM Krumholz EM Parent N Tu V Vaccarino Y Wang MJ Radford Readmission after hospitalization for congestive heart failure among Medicare beneficiaries Arch Intern Med 157 1997 99 104
23. WS Aronow I. Kronzon Effects of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular function Am J Cardiol 71 1993 602 604
24. JN Cohn G Johnson Veterans Administration Cooperative Study Group Heart failure with normal ejection fraction: the V-HeFT Study Circulation 81 Suppl III 1990 III-48 III-53
25. R Garg S. Yusuf Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA 273 1995 1450 1456
26. W. Grossman Diastolic dysfunction in congestive heart failure N Engl J Med 335 1991 1557 1564
27. RO Bonow JE. Udelson Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management Ann Intern Med 117 1992 502 510
28. H Schunkert VJ Dzau SS Tang AT Hirsch CS Apstein BH. Lorell Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload hypertrophy: effects on coronary resistance, contractility and relaxation J Clin Invest 86 1990 1913 1920
29. CG Brilla JS Janicki KT. Weber Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medical thickening of intramyocardial coronary arteries Circ Res 69 1991 107 115
30. C. Rosendorff The renin-angiotensin system and vascular hypertrophy J Am Coll Cardiol 28 1996 803 812
31. LE. Moses Measuring effects without randomized trials? Options, problems, challenges Med Care 33 1995 AS8 AS14
32. B. Pitt Angiotensin converting inhibitors in patients with congestive heart failure: a class effect? Am J Cardiol 68 1991 106 108